Efficacy observation of mesenchymal stem cells derived from human umbilical cord for therapy of hepatitis B patients with decompensated cirrhosis

Abstract

Objective To investigate short-term efficacy and security of transplantation of human umbilical cord mesenchymal stem cells(HUCMSCs)in the course of treatment of decompensated cirrhosis. Methods Ninety-six Hepatitis B patients with decompensated cirrhosis were enrolled, among which 50 were sbject to transplantation of HUCMSCs in addition to routine therapy(the treatment group) and the rest patients were underwent routine therapy(the control group). We observed the efficacy and security at 2, 4, 6 and 12 week of the treatment course. Results The symptoms of atigue, anorexia, bloating and edema were greatly relieved in both groups after 4 weeks, and sustained remission after 4-12 weeks. The overall survival rate was 96% after 12 weeks of the treatment group, 2 patients were died after 8 and 12 weeks of the HUCMSCs transplantation due to hepatic encephalopathy repecticely.Compared to the baseline, ALT, AST, TBil and ALB(albumin) were improved after 2, 4, 6 and 12 weeks in both groups(P 0.05). During the course of HUCMSCs tranplantation, the security was satisfied and no special side effects were observed. Conclusion The transplantation of HUCMSCs for therapy of Hepatitis B patients with decompensated cirrhosis is a safety and effective therapy, and can improved ALB, PT, PTA, liver function and clinical symptoms within a short period, which is an alternative method of treatment recommended. Key words: Liver cirrhosis; Hepatitis B; Stem cells; Treatment outcome